B cell-dependent subtypes and treatment-based immune correlates to survival in stage 3 and 4 lung adenocarcinomas.
Raju Paul S, Valiev I, Korek SE, Zyrin V, Shamsutdinova D, Gancharova O, Zaitsev A, Nuzhdina E, Davies DL, Dagogo-Jack I, Frenkel F, Brown JH, Hess JM, Viet S, Petersen JL, Wright CD, Ott HC, Auchincloss HG, Muniappan A, Shioda T, Lanuti M, Davis CM, Ehli EA, Hung YP, Mino-Kenudson M, Tsiper M, Sluder AE, Reeves PM, Kotlov N, Bagaev A, Ataullakhanov R, Poznansky MC.
Raju Paul S, et al. Among authors: shioda t.
FASEB Bioadv. 2023 Feb 16;5(4):156-170. doi: 10.1096/fba.2023-00009. eCollection 2023 Apr.
FASEB Bioadv. 2023.
PMID: 37020749
Free PMC article.